LAVA Therapeutics (NASDAQ:LVTX) Announces Earnings Results, Beats Estimates By $0.18 EPS

LAVA Therapeutics (NASDAQ:LVTX) announced its quarterly earnings data on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.18, Zacks reports. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.40 million.

LAVA Therapeutics Stock Down 0.8 %

Shares of LVTX stock traded down $0.01 during mid-day trading on Friday, hitting $1.29. 43,333 shares of the company’s stock were exchanged, compared to its average volume of 173,459. The stock has a market cap of $33.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.48. The stock has a 50-day simple moving average of $1.13 and a two-hundred day simple moving average of $1.37. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $3.57.

Analyst Ratings Changes

LVTX has been the topic of several research analyst reports. HC Wainwright restated a “neutral” rating and issued a $1.50 price objective (down from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. Leerink Partnrs lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.